For the quarter ending 2025-09-30, SHC had -$33,246K decrease in cash & cash equivalents over the period. $34,982K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 48,400 | -5,298 |
| Depreciation | 22,711 | 45,223 |
| Amortization of intangible assets | 5,649 | 30,597 |
| Loss on refinancing of debt | -1,087 | -80 |
| Deferred income taxes | 8,186 | -25,099 |
| Litigation settlement-Ethylene Oxide Tort Litigation Illinois | - | -64,943 |
| Share-based compensation expense | 7,949 | 15,361 |
| Litigation settlement-Ethylene Oxide Tort Litigation Georgia | - | 0 |
| Accretion of asset retirement obligations | 601 | 1,136 |
| Unrealized foreign exchange loss (gain) | 10,508 | -18,886 |
| Unrealized (gain) loss on derivatives not designated as hedging instruments | -1,389 | 1,994 |
| Amortization of debt issuance costs | 1,305 | 2,645 |
| Other | 1,275 | 2,474 |
| Accounts receivable | 6,428 | -9,084 |
| Inventories | -9,040 | 7,663 |
| Other current assets | 4,698 | 14,250 |
| Accounts payable | -8,375 | 5,573 |
| Accrued liabilities | 27,793 | -14,514 |
| Litigation settlement-Ethylene Oxide Tort Litigation Illinois | 34,000 | - |
| Litigation settlement-Ethylene Oxide Tort Litigation Georgia | 0 | - |
| Income taxes payable / receivable, net | -1,332 | -8,212 |
| Other liabilities | -117 | -27 |
| Other long-term assets | -720 | 1,060 |
| Net cash provided by operating activities | 71,154 | 112,937 |
| Purchases of property, plant and equipment | 36,172 | 51,147 |
| Other investing activities | -2,837 | -37 |
| Net cash used in investing activities | -33,335 | -51,110 |
| Proceeds from long-term borrowings | 0 | 0 |
| Payment of long-term borrowings | 75,000 | 7,547 |
| Payments of debt issuance costs and debt discount | 1,593 | 2,326 |
| Buyout of leased facility | 0 | 0 |
| Shares withheld for employee taxes on equity awards | 207 | 3,654 |
| Other financing activities | -539 | -1,493 |
| Net cash used in financing activities | -77,339 | -15,020 |
| Effect of exchange rate changes on cash and cash equivalents | 6,274 | 8,600 |
| Net increase in cash and cash equivalents, including restricted cash | -33,246 | 55,407 |
| Cash and cash equivalents at beginning of period | 278,865 | - |
| Cash and cash equivalents at end of period | 301,026 | - |
Sotera Health Co (SHC)
Sotera Health Co (SHC)